NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Thanks Gary, you are correct that the price of DCVax-L could go up instead of down, and my valuation could be a lot higher. But, I purposely wanted to be very conservative with my valuation analysis.

Also, I do expect significant manufacturing cost reductions after the Flaskworks Eden system is incorporated to scale-up DCVax-L production capacity.

In addition, as the number of solid tumor cancer patients treated with DCVax-L increases annually, there will be additional cost savings due to economies of scale.